The BEAT-ROP study demonstrated that treatment of zone I and zone II ROP with intravitreal Bevacizumab (Monoclonal antibody, Anti VEGF) was superior to the laser treatment [5]. This evidence concerns the gene VEGFA and retinopathy of prematurity.